Drugs / MDR-102
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03605654 | Dec 2024 → Sep 2026 | transplant rejection | Medeor Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDR-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03605654 ↗ |
| Modality | Cell therapy | “novel cell-based therapy” NCT03605654 ↗ |